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Candida albicans is part of the human gastrointestinal (GI) microbiota. To better
understand how C. albicans efficiently establishes GI colonisation, we competitively
challenged growth of 572 signature‐tagged strains (~10% genome coverage), each
conditionally overexpressing a single gene, in the murine gut. We identified CRZ2, a
transcription factor whose overexpression and deletion respectively increased and
decreased early GI colonisation. Using clues from genome‐wide expression and
gene‐set enrichment analyses, we found that the optimal activity of Crz2p occurs
under hypoxia at 37°C, as evidenced by both phenotypic and transcriptomic analyses
following CRZ2 genetic perturbation. Consistent with early colonisation of the GI
tract, we show that CRZ2 overexpression confers resistance to acidic pH and bile
salts, suggesting an adaptation to the upper sections of the gut. Genome‐wide
location analyses revealed that Crz2p directly modulates the expression of many
mannosyltransferase‐ and cell‐wall protein‐encoding genes, suggesting a link
with cell‐wall function. We show that CRZ2 overexpression alters cell‐wall
phosphomannan abundance and increases sensitivity to tunicamycin, suggesting a
role in protein glycosylation. Our study reflects the powerful use of gene overexpres-
sion as a complementary approach to gene deletion to identify relevant biological
pathways involved in C. albicans interaction with the host environment.
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Candida albicans is part of the human microbiota. As a commensal,
C. albicans is present within the gastrointestinal (GI) and genital tracts
of healthy humans. In patients with altered immunity or those under-
going broad‐spectrum antibiotic treatment, C. albicans colonises the GI
tract and may cause disease (Shankar et al., 2015; Zaborin et al., 2014).
C. albicans represents the most frequently isolated species from
patients with fungemia and is responsible for a significant mortality
rate among intensive‐care unit patients (Delaloye & Calandra, 2014).
C. albicans may also participate in the onset of the inflammatory
bowel disease through disruption of the gut microbial equilibrium
(i.e., dysbiosis; Sokol et al., 2017). Consequently, understanding the
mechanisms of C. albicans colonisation/invasion of body niches would
help in proposing new GI disease‐preventive strategies and/or targets
for the development of antifungal agents.
Owing to completion of the C. albicans genome sequencing
project (Braun et al., 2005), functional genomics studies in C. albicans
have considerably increased over the past decade. The construction
of biological resources (e.g., gene knock‐out collections) combined
with the use of genomics technologies has significantly contributed
to our understanding of how C. albicans expresses its pathogenicity
traits. Powerful in vivo screens identified a handful number of tran-
scription factors (TFs) with a role in GI tract colonisation (LYS144,
TYE7, ZCF8, ZFU2, and TRY4; Bohm et al., 2017; Perez, Kumamoto,
& Johnson, 2013), establishment of systemic infection (LYS14,
ZCF21, RGT1, SEF1, and others; Noble et al., 2010; Perez et al.,
2013; Vandeputte, Ischer, Sanglard, & Coste, 2011), or both processes
(RTG1, RTG3, and HMS1; Perez et al., 2013; Vandeputte et al., 2011).
These screens relied on competitive phenotypic profiling of signa-
ture‐tagged (i.e., barcoded) gene‐deletion mutants in mouse models
of GI tract colonisation or systemic infection. Additional TFs with a
role in adherence to abiotic substrates (e.g., CRZ2, BCR1, and ACE2;
Finkel et al., 2012) or biofilm formation (e.g., BCR1 and ROB1; Nobile
et al., 2012; Nobile & Mitchell, 2005) have been identified using
in vitro screens of TF‐mutant collections (Davis et al., 2002; Homann,
Dea, Noble, & Johnson, 2009). These TFs modulate the expression of
target genes within highly intricate regulatory networks involving
direct cross‐talks between TFs (Nobile et al., 2012) and the regulation
of the expression of specific effectors such as adhesins (ALS1 and
HWP1; Nobile et al., 2012; Nobile & Mitchell, 2005), cell‐surface
genes, and hyphal/virulence‐associated genes (Finkel et al., 2012).
The biological circuitries under the control of TFs involved in the
expression of C. albicans pathogenicity traits can be inferred from a
combination of genome‐wide expression and location (ChIP‐chip/
Seq) technologies (Chen, Pande, French, Tuch, & Noble, 2011; Perez
et al., 2013; Znaidi, Nesseir, Chauvel, Rossignol, & d'Enfert, 2013;
Znaidi et al., 2014). As an example, the role of the Sfu1p and Sef1p
TFs in C. albicans ability to respectively act as a commensal and a sys-
temic‐infection pathogen through modulation of iron homoeostasis
has been elegantly shown by combining ChIP‐chip and transcriptomics
experiments (Chen, Pande, et al., 2011). The same approaches also
demonstrated that RTG1, RTG3, TYE7, and LYS144 mediate GI tract
colonisation by controlling the expression of genes involved in the
acquisition and metabolism of specific nutrients, reflecting theimportance of nutrient sensing/uptake during C. albicans commensal-
ism (Perez & Johnson, 2014). Such systems biology‐driven strategies
are therefore cornerstone for mapping biological networks operating
during C. albicans interaction with the host.
Gene overexpression is another powerful genetic approach for the
discovery of pathways and phenotypes (Chua et al., 2006; Douglas
et al., 2012; Sopko et al., 2006). It mimics gain‐of‐function mutations,
complements loss‐of‐function phenotypes, and allows the function of
both essential and non‐essential genes to be investigated (Prelich,
2012). Because diploidy and lack of a complete sexual cycle hamper
the use of classical genetics in C. albicans, gene overexpression is
regarded as an attractive alternative strategy for performing functional
large‐scale studies in this pathogen. We have previously established
C. albicans strain collections for conditional gene‐overexpression using
the pNIM1 (Park & Morschhauser, 2005) and pNIMX (Chauvel et al.,
2012) systems that respectively enable moderate and potent tetracy-
cline derivative‐induced expression (Chauvel et al., 2012). Strains from
our collections carry unique 20‐bp signature tags that allow simulta-
neous phenotyping in mixed‐population experiments (Chauvel et al.,
2012).We successfully used a collectionwithmoderate, pNIM1‐driven,
overexpression of 531 open‐reading frames (ORFs) for the identifica-
tion of genes involved in biofilm formation, one of the major pathoge-
nicity traits of C. albicans (Cabral et al., 2014). In the current report,
we established a new library carrying 572 signature‐tagged strains with
potent, pNIMX‐driven, conditional overexpression (Chauvel et al.,
2012). We used it in a mouse model of GI tract colonisation to propose
a new role for theTF Crz2p: the regulation of processes controlling the
ability of C. albicans to efficiently proliferate within the host.2 | RESULTS
2.1 | Construction of a new signature‐tagged
overexpression strain collection with enhanced
tetracycline promoter‐driven overexpression
We previously generated a signature‐tagged C. albicans overexpression
collection totalling 274 ORFs with tetracycline‐derivative inducible
expression (PTET) based on the pNIMX expression system (Figure 1a;
Chauvel et al., 2012). In this study, we expanded this collection to
encompass 572 ORFs (~10% genome coverage), including genes
encoding (or predicted to encode) transcriptional regulators (183
ORFs), phosphatases (33 ORFs), kinases (77 ORFs), cell wall genes (74
ORFs), DNA replication/recombination/repair genes (109 ORFs), and
signalling/other category genes (96 genes; Table S1, Figure 1b).2.2 | Identification of genes whose overexpression
alters both Candida albicans fitness and morphology
in vitro
We used our new collection to identify genes whose overexpression
alters C. albicans fitness during growth under standard laboratory con-
ditions (i.e., rich medium, normoxia at 30°C). The presence of a unique
20‐bp barcode sequence (Figure 1a) allows quantification of strain
abundance during competitive growth, as we previously showed
FIGURE 1 Construction of a new
tetracycline‐inducible overexpression strain
collection with enhanced overexpression
efficiency. (a) Schematic representation of the
StuI‐linearised, signature‐tagged (Barcode),
overexpression vector that was used to create
the 572‐strain collection. Expression of each
of the 572 open‐reading frames (ORFs; orf19.
XXXX; dark grey rectangle) is under the
control of the tetracycline‐inducible promoter
(PTet, black box), which is activated in the
presence of doxycycline (horizontal arrow).
The overexpression cassette is integrated at
the RPS1 locus following a StuI digestion (3′
RPS1, 5′ RPS1). The ORF is flanked by the
lambda‐phage attachment sequences R1 and
R2 (open triangles) that allowed
recombination‐mediated transfer of ORFs
from an entry vector collection to the
destination barcoded vectors. A unique 20‐bp
sequence (Barcode) serves as a strain
identifier and allows the relative abundance of
each strain to be quantified in mixed‐
population experiments. Every strain also
carries the SacII, KpnI‐linearised pNIMX
construct (Chauvel et al., 2012) integrated at
the ADH1 locus and carrying the Candida
albicans reverse tetracycline transcriptional
activator (cartTA) placed under the control of
the TDH3 promoter (PTDH3). Transformant
selection markers are depicted with open
arrows. (b) Pie chart showing the functional
categories of the 572 ORFs included in the
overexpression strain collection. The number
of ORFs is indicated between parentheses
F2
F3
ZNAIDI ET AL. 3 of 21(Cabral et al., 2014). The 572 strains were competitively grown in
Yeast Extract‐Peptone‐Dextrose (YPD) medium at 30°C for 20 gener-
ations in the absence or presence of 40 μg ml−1 doxycycline (Dox),
followed by genomic DNA extraction, barcode polymerase chain reac-
tion (PCR)‐amplification, cyanine‐dye labelling, and hybridization to
barcode arrays (see Section 4 for details). We found 25 genes whose
overexpression decreased C. albicans fitness (Figure 2a, Table S2, Z‐
score ≤ −2; P < 0.05), including 10 genes involved (or predicted to
be involved) in DNA damage response or cell‐cycle progression
(RAD53, RAD51, RME1, orf19.2781, KIN3, BEM1, HSL1, orf19.2097,
orf19.1792, and PPH21), 9 genes involved in hyphal development
(CPH1, SFL2, BRG1, SFL1, YCK2, RDI1, FKH2, KIP4, and RFG1), and 6
genes encoding signalling proteins or exerting other/yet unknown
functions (orf19.996, orf19.676, GZF3, FHL1, BUD5, and orf19.1189;
Figure 2a). Our screen reconfirmed the genes that we previously showed
to affect C. albicans fitness using the pNIM1 system (RAD53, RAD51,
SFL2, and orf19.2781; Cabral et al., 2014) and identified additional hits
(Figure 2a), suggesting that enhancing overexpression levels (pNIMX
achieves approximately fivefold higher overexpression levels as
compared with pNIM1) increases the sensitivity of our assay. We
validated our microarray data using liquid growth assay of individually
grown strains (Figure 2b, see Section 4). Interestingly, overexpression
of some of the fitness‐defect genes altered cell morphology (RAD53,
RAD51, RME1, FKH2, orf19.2097, and orf19.1189) or induced cell–cellaggregation (YCK2, BEM1, HSL1, and BUD5; Figure 2c). As morphology
alterations affect turbidity measurements (Cabral et al., 2014), these
strains were omitted from our liquid growth assay. Taken together, these
data validated our competitive phenotypic profilingwith the new pNIMX
collection and identified new genes whose overexpression affects
C. albicans fitness, morphology, and cell–cell aggregation.2.3 | Identification of genes whose overexpression
alters colonisation of the mammalian GI tract
We screened our collection, in vivo, for genes whose overexpression
alters C. albicans ability to colonise the murine gut (Figure S1 for a
schematic representation of our strategy). Mice were given
gentamycin‐ and streptomycin‐containing drinking water, supple-
mented (n = 5 mice) or not (control, n = 4 mice) with 2 mg ml−1 doxy-
cycline, and then inoculated by gavage with ~5 × 107 cells from the
572‐strain pool (Figure S1, see Section 4). Stools were collected
10 days post‐gavage. Total genomic DNA was extracted from both
faeces and inoculum samples, and the relative abundance of the
strains was assessed by microarrays (Figure S1). We found one hit
out of the 572‐competing strains displaying increased abundance in
dox‐treated mice (Figure 3a, upper panel, +Dox) and unaltered abun-
dance in dox‐untreated animals (Figure 3a, lower panel, −Dox). This
hit matched CRZ2 that encodes a zinc finger TF of the Cys2His2 family
FIGURE 2 Competitive fitness profiling of Candida albicans overexpression strains under standard laboratory growth conditions. (a) The effect of
gene overexpression on cell growth was tested in liquid YPD medium at 30°C under vigorous shaking (standard laboratory growth conditions,
normoxia) in the absence or presence of 40 μg ml−1 doxycycline (Dox) for 18 generations. The experiment was performed using n = 3 biological
replicates. Samples were subjected to genomic DNA extraction, polymerase chain reaction‐amplification, indirect fluorescent dye labelling (Dox‐
treated sample: Cy5‐labelled; untreated control: Cy3‐labelled), and hybridization to a barcode microarray with both forward and reverse‐
complemented probes for each tag (two black circles next to each gene name/orf19 nomenclature represent forward and reverse‐complemented
probe sequences). Fitness scores (Z‐score for each tag) are shown on the y axis. The corresponding probe number ranked using the orf19
nomenclature in ascending order is shown on the x axis. Z‐score calculations were performed using ArrayPipe v2.0. Dashed lines correspond to the
Z‐score values +2.0 (upper line) and −2.0 (lower line). Names or orf19 nomenclature of the genes whose overexpression alters strain fitness are
shown. (b) Confirmation of the microarray data by liquid growth assay (YPD, 30°C) of strains overexpressing PPH21, orf19.1792, BUD5, FHL1,
orf19.2781, and orf19.996, together with a control strain carrying the empty vector (CTRL) grown 3 times independently in a 96‐well plate using a
TECAN Infinite M200 device (see Section 4). Doubling time in hours (average from n = 3 biological replicates and error bars denote standard
deviations) is indicated on the y axis for each strain grown in the absence (grey bar, −Dox) or presence (black bar, +Dox) of 40 μg ml−1 Dox;
statistical significance was assigned (P < 0.05, asterisks) by performing a two‐tailed Student's t tests. (c) Phenotypic analysis of a subset of strains
overexpressing the indicated genes or control strain (CTRL). Strains were microscopically examined (40× magnification) immediately after being
subjected to the fitness profiling assay described in (b) +Dox, dox treatment (40 μg ml−1); −Dox, untreated samples
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(Kullas, Martin, & Davis, 2007). To validate our microarray data, we
performed quantitative PCR (qPCR) assays and specifically quantified
the relative abundance of the CRZ2 overexpression strain in pooled
mouse stools from dox‐treated/untreated cages (housing three mice
each) as compared with its abundance in the inoculum (Figure 3b).
The CRZ2‐overexpressing strain was more abundant in stools from
dox‐treated mice, whereas its abundance was unaltered in stools from
dox‐untreated animals (Figure 3b). Unchanged strain abundance was
observed for four randomly selected strains (orf19.3088, PGA37,
CNB1, and IHD1, Figure 3b). Under standard laboratory growth condi-
tions, in vitro, the abundance (Figure 2, Table S2) or growth rate
(Figure S2A) of the CRZ2‐overexpressing strain was unaltered,
reflecting the specificity of our in vivo assay. We have also inspected
colony size/morphology (e.g., GUT phenotype) and cellularmorphology following passage through the mouse. We did not detect
clear differences in morphology and/or size. We have also tested
whether overexpression of CRZ2 could alter hyphal growth in both
rich and hyphae‐inducing media and found no difference compared
with the control strain.
To test whether the CRZ2 overexpression phenotype could be
reproduced in a 1:1 competition assay, we gavaged dox‐treated and
dox‐untreated mice with an inoculum containing an equal mixture of
a strain co‐expressing the green fluorescent protein (GFP, under the
control of PTDH3) and CRZ2 (under the control of PTET) versus a strain
expressing the blue fluorescent protein (BFP, under the control of
PTDH3) and carrying an empty‐vector control (see Section 4). Stools
were recovered 4 days post‐gavage, homogenised, and plated on
gentamycin‐ and chloramphenicol‐containing YPD medium during
2 days at 30°C. The resulting C. albicans colony‐forming units (CFUs)
FIGURE 3 CRZ2 contributes to Candida albicans fitness during
gastrointestinal colonisation. (a) Genomic DNA was extracted from
faeces of BALB/c female mice at Day 10 post‐gavage with an
inoculum of 572 PTET‐inducible‐overexpression strains. Barcodes were
polymerase chain reaction‐amplified from both faecal (Cy5‐labelled)
and inoculum (Cy3‐labelled) genomic DNA and hybridized to barcode
arrays (Figure S1). Data are presented as described in legend to
Figure 2a. The CRZ2 tag displays increased abundance (positive Z‐
score) in dox‐treated mice (+Dox, n = 5 mice, P = 0.01) but not in dox‐
untreated animals (−Dox, Control, n = 4 mice). (b) Pooled faecal
samples, at Day 10 post‐gavage, from two independent cages housing
three dox‐treated (+Dox, black bars) or three dox‐untreated (−Dox,
grey bars) mice were subjected to genomic DNA extraction and up to
seven quantitative polymerase chain reaction assays to determine the
average fold‐change abundance (y axis, error bars denote standard
deviations) of strain PTET‐CRZ2 (CRZ2) as compared with its abundance
in the inoculum. Strains orf19.3088, PGA37, CNB1, and IHD1 were
used as negative controls, and ACT1 served as a normalisation control.
One representative result out of two is shown. Statistical significance
was assessed by a two‐tailed Student's t test (asterisk, P < 0.05). (c and
d) Median competitive indexes (CIs, y axis) at Day 4 post‐gavage of
strains PTET‐CRZ2 (green fluorescent protein [GFP]‐labelled) versus
control (blue fluorescent protein [BFP]‐labelled) in dox‐treated (+Dox,
n = 6) and dox‐untreated (−Dox, n = 12) mice (c) and two independent
crz2Δ/crz2Δ mutants (crz2Δ/Δ #1 and #2, GFP‐labelled) versus
control (CTRL, BFP‐labelled) or the parental wild‐type strain (WT,
GFP‐labelled) versus control (CTRL, BFP‐labelled) (d) were determined
by flow cytometry analyses (see Section 4). Statistical significance was
assessed using a non‐parametric Mann–Whitney test (two‐tailed;
*P < 0.05; **P < 0.01). Dox: doxycycline
ZNAIDI ET AL. 5 of 21were pooled, and the relative abundance of strains carrying PTET‐CRZ2
(GFP) and control plasmid (BFP) was quantified with fluorescence‐
activated cell sorting (Figure 3c, see Section 4). The CFUs from dox‐
treated mice displayed increased median competitive index (CI: ~2.9)
for the GFP‐positive (CRZ2) strain as compared with the BFP control
strain (Figure 3c), whereas those from dox‐untreated animals showed
a median CI close to 1.0 (Figure 3c). The effect of deleting CRZ2 was
also examined using the same strategy, except that dox treatment
was omitted from the assay because we used non‐conditional CRZ2
deletion mutants (see Section 4). We tested two independently gener-
ated crz2−/− strains and found that both mutants failed to maintain
efficient colonisation, as judged by the significant decrease in their
median CIs (Figure 3d).
We further measured the relative abundance of the CRZ2 overex-
pression and deletion mutants at later time points using our 1:1 com-
petition assay (Days 10 and 14). Surprisingly, the effect of CRZ2
overexpression and deletion on GI colonisation was not sustained
over time (Figure S2B,C), which may reflect an adaptive process con-
fined to the upper sections of the digestive tract (see below). Yet,
increased abundance of the CRZ2‐overexpressing strain was still
detected in our 1:571 competitive screen on Day 10 post‐gavage
(Figure 3b). To explain this discrepancy, we simulated competitive
growth of a strain with a fitness of either 2.2 or 2.1 relative to a strain
with a fitness of 2.0 using two different ratios: 1:1 and 1:571
(Table S5). We calculated the corresponding CIs for cultures with a
1:1 ratio versus those with a 1:571 ratio (Table S5). Consistent with
our observation, we found that CIs evolve differently according to
the competition ratio and time, inuring to the benefit of the 1:571
comparison (see Graph in Table S5).2.4 | Crz2p activates the hypoxic transcriptional
program and modulates the expression of cell‐surface
genes
Crz2p was shown to regulate the expression of a subset of Zap1p tar-
gets involved in biofilm formation using nanoString transcript profiling
of 293 genes (Finkel et al., 2012). To comprehensively define the reg-
ulatory network of Crz2p and better understand how CRZ2 contrib-
utes to colonisation of the GI tract, we performed whole‐genome
transcript profiling of the strain overexpressing CRZ2. The PTET‐CRZ2
strain was grown in YPD medium at 30°C, in the absence or presence
of dox, for 2 and 4 hr to investigate early (2 hr, those that could reflect
direct targets) versus later (4 hr, including direct and indirect targets)
transcriptional programming (see Section 4). At time point 2 hr, 110
and 66 genes were respectively upregulated (fold‐change ≥1.5,
P < 0.05) and downregulated (fold‐change ≤−1.5, P < 0.05) in response
to CRZ2 induction (Figure 4a, Table S6). At time point 4 hr, 220 and
205 genes were respectively upregulated and downregulated using
the same criteria (Figure 4a, Table S6). Among the PTET‐CRZ2 upregu-
lated genes, we found a high proportion of those encoding
(or predicted to encode) cell‐surface proteins (e.g., PGA6, ECM331,
PLB1, PLB4.5, KRE1, and SCW11), mannosyltransferases (e.g., MNN1,
MNN24, MNN22, and BMT5), proteins involved in methionine/cyste-
ine metabolism (e.g., MET15, MET3, MET10, and ECM17), and small
molecule/amino‐acid transporters (e.g., orf19.4690, SSU1, FRP3,
FIGURE 4 Transcriptomic analysis of CRZ2 overexpression strains. (a) Heat maps of the 40 highest transcriptionally modulated genes (absolute
n‐fold changes are shown) in PTET‐CRZ2 transcript profiling data at time points 2 and 4 hr post‐induction with 40 μg ml
−1 doxycycline (combination
of three biological replicates in each condition). The most upregulated (descending signal intensity, sorted by average expression between 2 and
4 hr, left panel) or downregulated (ascending signal intensity, sorted by average expression between 2 and 4 hr, right panel) genes in dox‐treated
versus untreated cells are indicated with their corresponding name or orf19 nomenclature on the right side of each panel. Heat maps were
constructed using Genesis version 1.7.6 (Sturn, Quackenbush, & Trajanoski, 2002). (b and c) Gene‐set enrichment analyses maps at time points
2 hr (b) and 4 hr (c) post‐induction of CRZ2 gene expression. Functional enrichment among the upregulated and downregulated genes is depicted
with red and blue spheres, respectively. Sphere size is proportional to the number of genes. Network motif thickness is proportional to the extent
of overlap in the list of genes between each node (blue/red spheres). Selected functional categories are indicated with dashed circles. Highlighted
subnetworks are zoomed in (open large boxes in [b]). (d) Venn diagram of the overlap (45 genes) between genes that are induced by PTET‐driven
overexpression of CRZ2 (269 genes) and those that are transcriptionally upregulated in mouse gastrointestinal (GI) tract (408 genes) as identified
by Rosenbach et al. (2010). Statistical significance (P = 1.1 × 10−9) was assessed using a hypergeometric test. TF: transcription factor
6 of 21 ZNAIDI ET AL.FRP6, and OPT1; Figure 4a, Table S6). On the other hand, many cell
wall/surface genes (e.g., IFF11, RHD3, ALS4, CSP2, CSH1, ALS2, and
PGA10) and genes involved in signalling (ASR2 and SRR1) and carbohy-
drate metabolism (PCK1, DLD2, and ARA1) were downregulated
(Figure 4a, Table S6). As a control, dox treatment alone does not
significantly alter gene expression (Figure S3). Only 13 and 9 geneswere upregulated and downregulated with maximum fold‐change
values of 2.0 and −2.5, respectively (Table S7), including 10 genes
displaying increased fold‐change due to a skew in the distribution of
high‐intensity signal (Figure S3B and Table S7).
To get a global view of the metabolic processes and pathways
that were significantly transcriptionally modulated by CRZ2
ZNAIDI ET AL. 7 of 21induction, we performed gene‐set enrichment analyses (GSEA) and
used the Cytoscape GSEA plugin (Sellam et al., 2014) to map the
biological pathways and gene sets that are enriched among the
upregulated (red spheres) and downregulated (blue spheres) genes
at time points 2 hr (Figure 4b) and 4 hr (Figure 4c; see Section 4).
During the early (2 hr) transcriptional response to CRZ2 induction,
there was a striking enrichment of processes pertaining to mitochon-
dria and proteasome function among the downregulated genes
(Figure 4b, blue sphere‐containing networks), with a noticeable
downregulation of aerobic respiration (Figure 4b, marked in blue).
Conversely, hypoxic genes were significantly enriched among the
upregulated genes (Figure 4b, marked in red), together with pro-
cesses pertaining to hexose metabolism (e.g., glycolysis and carbohy-
drate biosynthesis), sulfur amino‐acid metabolism, positive regulation
of transcription, and metal/small molecule transport (Figure 4b, red
sphere‐containing networks). The genes encoding cell wall compo-
nents (Figure 4b, lower boxed network) and those participating in
interaction with the host (Figure 4b, upper boxed network) were also
remarkably enriched. At time point 4 hr, ribosome biogenesis and
assembly along with gene sets that are downregulated during various
stresses (e.g., oxidative, osmotic, and heavy metal stresses) or by
specific signalling proteins (Cyr1p, Cdc5p, Cap2p, and Sko1p) were
significantly overrepresented among the CRZ2‐induced genes
(Figure 4c, upper left network). The sulfur amino‐acid metabolism
genes and those encoding cell wall components or participating in
C. albicans–host interaction were still enriched (Figure 4c, upper right
and lower left networks), whereas genes involved in lipid/sterol
metabolism and those encoding components (or functional compo-
nents) of the endoplasmic reticulum (ER) became overrepresented
(Figure 4c, upper right subnetworks).
Rosenbach, Dignard, Pierce, Whiteway, and Kumamoto (2010)
analysed the genome‐wide transcriptional changes of C. albicans
during GI tract colonisation as compared with laboratory growth
conditions. They identified a set of 408 genes specifically upregulated
in the mouse gut. We compared the list of genes that are significantly
upregulated by PTET‐CRZ2 to those identified in Rosenbach et al.
(Figure 4d). Among the 408 genes that are induced in the gut, 45 were
also upregulated by PTET‐CRZ2 at time points 2 or 4 hr (out of 269
genes, Figure 4d), yielding a ~2.6‐fold enrichment of mouse gut‐
induced genes in our dataset (P = 1.1 × 10−9 using a hypergeometric
test, Figure 4d). Interestingly, the GO terms “glycolytic process”
(ADH1, ENO1, FBA1, and TDH3; P = 1.11 × 10−3), “cell surface”
(ADH1, ENO1, FBA1, HWP1, IHD1, PGA54, SAP9, SUN41, TDH3, and
TOS1; P = 5.25 × 10−5), and “symbiosis, encompassing mutualism
through parasitism” (ADH1, ENO1, FBA1, HWP1, SAP9, SUN41, and
TDH3; P = 6.68 × 10−3) were particularly overrepresented among the
45 gut‐ and CRZ2‐induced genes, possibly reflecting a role of CRZ2
in adaptation to hypoxia and the modulation of cell‐wall function dur-
ing GI colonisation. We validated our expression microarray data by
quantitative reverse transcription‐PCR (qRT‐PCR) analyses of selected
genes using ACT1 as a negative control for differential expression
(Figure S4).
Taken together, our results indicate that CRZ2 overexpression
turns off aerobic respiration and activates the hypoxic transcrip-
tional signatures, while inducing the expression of cell wall genestogether with genes involved in GI colonisation and interaction with
the host.
2.5 | Crz2p binds to the promoter of
mannosyltransferase‐ and cell wall protein‐encoding
genes
To determine if the CRZ2 transcriptionally modulated genes
were directly regulated by Crz2p, we performed chromatin immuno-
precipitation coupled with hybridization to whole‐genome tiling
microarrays in strains expressing a tandem affinity purification
(TAP)‐tagged versus a wild‐type version of CRZ2, both placed under
the control of PTET and grown for 4 hr in the presence of dox (see
Section 4). Using the CisGenome peak finding algorithm (Ji et al.,
2008), we identified 331 Crz2p‐binding peaks (Tables S8–S10).
Among these peaks, 194 were located in promoter regions that
were clearly associated with unique targets, 113 were located in
promoters shared by two ORFs in opposite orientations, and the
remaining 24 were found within ORF regions (Table S10). In many
occurrences, more than one peak was found in the promoter of
a given gene (Figure 5a, upper panel, CRZ2 locus), suggesting
the presence of more than one binding site for Crz2p or the occur-
rence of functional interactions with additional DNA‐binding proteins
as previously observed (Znaidi et al., 2013). Overall, the 331 peaks
matched 342 target genes, assuming that two ORFs sharing the
same bound promoter are both direct targets of Crz2p. Many of
the Crz2p‐bound targets encode cell wall proteins (e.g., ALS3,
ECM331, PLB1, and RHD3) or mannosyltransferases (e.g., MNN1,
MNN22, and RHD1; Figure 5a) and overlapped with genes transcrip-
tionally modulated by Crz2p (Figure 4a). Crz2p also binds to its
own promoter, suggesting a transcriptional autoregulatory loop
(Figure 5a). We confirmed our ChIP‐chip data by qPCR analyses
of selected targets (CRZ2, MNN1, ECM331, MNN22, RHD1,
and RHD3) using ACT1 as a negative control for Crz2p binding
(Figure 5b).
We conducted motif‐enrichment analyses using DNA sequences
encompassing ±250 bp around peak summits in Crz2p binding data.
The Regulatory Sequence Analysis Tools peak‐motifs algorithm
(http://rsat.ulb.ac.be/rsat/ [Thomas‐Chollier et al., 2012]) was used
for motif discovery and motif comparison with knownTF binding sites
(see Section 4). We found two related high‐scoring motifs, 5′‐cTAAG
CCtcc‐3′ and 5′‐cTAAGCCaca‐3′ (Figure 5c), with significance coeffi-
cients of >60 (sig scores = −log10 [E‐value], resulting from a binomial
test). Motif comparison with known TF binding sites indicated that
both motifs were similar to the Saccharomyces cerevisiae Crz1p motif
(5′‐aGCCNC‐3′; Figure 5c, bottom panel), which may reflect the
phylogenetic proximity of Crz1p and Crz2p.
2.6 | The Crz2p regulatory network
We combined our genome‐wide expression and location data to
map the direct regulatory interactions occurring between Crz2p
and its target genes (Figure 6). This enabled the identification of
additional bona fide Crz2p binding peaks matching 79 targets
that were not detected by the peak‐finding algorithm, and these were
FIGURE 5 Genome‐wide location of transcription factor Crz2p. (a) Crz2p occupancies along 25‐kb intervals of selected locations from the
Candida albicans genome (Assembly 20, the corresponding chromosome numbers are indicated at the left of each panel). Plotted are the
relative signal intensities of the 60‐bp probes covering the whole C. albicans genome following enrichment of the tandem affinity purification
(TAP)‐tagged Crz2p‐coimmunoprecipitated DNA relative to DNA from a mock immunoprecipitation (i.e., in an untagged‐strain background). Data
from one ChIP‐chip experiment out of two are shown. Some binding‐enrichment signals extend beyond the maximum graduations (−5.0 and +5.0
fold‐enrichment). The orientation of each open‐reading frames is depicted by the arrowed black rectangle. Binding maps were generated using the
Integrated Genomics Viewer genome browser (Thorvaldsdottir et al., 2012). (b) Quantification of DNA enrichment following immunoprecipitation
of TAP‐tagged Crz2p at the promoters of CRZ2, MNN1, ECM331, MNN22, RHD1, and RHD3 by quantitative polymerase chain reaction assays in
strains C251, C252 (tagged), C255 and C257 (control strains; untagged). Bars represent absolute relative enrichment values (n‐fold, y axis) of TAP‐
Crz2p coimmunoprecipitated DNA as compared with DNA from mock immunoprecipitation. Error bars denote standard deviations from the mean
(using data from three quantitative polymerase chain reaction assays with two biological replicates in each assay, assumed as n = 6). All enrichment
values were statistically significant using a two‐tailed Student's t test that compares binding enrichment values at the indicated loci to those at the
ACT1 locus (negative control; *P < 0.05; **P < 0.01). (c) Motif logos of conserved sequences in Crz2p‐enriched DNA fragments. DNA sequences
encompassing ±250 bp around peak summits in Crz2p binding data were used as input for motif discovery by Regulatory Sequence Analysis Tool
peak‐motifs (http://rsat.ulb.ac.be/rsat/ [Thomas‐Chollier et al., 2012]) algorithm. Two related high‐scoring motifs are shown (Motif #1 and Motif
#2), together with the aligned Saccharomyces cerevisiae Crz1p motif (bottom logo)
8 of 21 ZNAIDI ET AL.added to the list of Crz2p targets (Table S9, Figure 6). We found
102 targets that were both bound and transcriptionally induced
by Crz2p (Figure 6, red box) versus 63 genes that were both boundand transcriptionally repressed (Figure 6, green box), indicating
that Crz2p acts as both activator and repressor of gene expression.
A high proportion of the Crz2p directly induced genes encodes
FIGURE 6 The Crz2p regulatory network. Venn diagrams of the overlap between genes that are transcriptionally modulated by PTET‐CRZ2 at
time points 2 and 4 hr (gene expression fold‐change ≥1.5; P < 0.05) and bound by Crz2p. Numbers in Venn diagrams indicate the number of
genes, and those between parentheses indicate the total number of upregulated (light red circles), downregulated (light green circles), and bound
(light blue circle) genes. Circled numbers indicate the number of genes that are both bound and transcriptionally modulated by Crz2p. The name of
these genes (or their orf19 nomenclature) and the functional categories to which they belong are shown in the linked red (103 bound and
upregulated genes) and green (63 bound and downregulated genes) boxes
ZNAIDI ET AL. 9 of 21mannosyltransferases (GO:0005975, “Carbohydrate metabolic pro-
cess,” P = 2.31 × 10−3), cell wall proteins (GO:0005618, “Cell wall,”
P = 2.23 × 10−7), and membrane transporters (GO:0005215, “Trans-
porter activity,” P = 0.044; Figure 6, red box). Similarly, a subset of
genes encoding cell wall proteins, membrane transporters, and
mannosyltransferases were directly downregulated (Figure 6, green
box). Most of the membrane‐transporter genes are involved (or are
predicted to be involved) in amino‐acid/peptide (OPT1, OPT7,
PTR22, CAN3, GAP4, and HIP1) or metal/ion (ALR1, orf19.4690,
FLC2, FTR2, PHO84, and CRP1) transport.
Taken together, our data indicate that Crz2p acts as both
activator and repressor of gene expression and directly regulates the
expression of genes potentially linked to cell wall function and to
carbohydrate metabolism.FIGURE 7 CRZ2 mutants exhibit altered respiration. (a) Antimycin A su
(CIp10‐PTDH3‐CRZ2 and CIp10‐PTET‐CRZ2) strains was tested by spot assa
20 μg ml−1 antimycin A + 3 μg ml−1 anhydrotetracycline (aTc). The CIp10‐
respectively used as a control. Plates were incubated at 30°C for 2 days. (
overlay was poured on patches of the same strains to reconfirm respiratio2.7 | CRZ2 mutants exhibit altered respiration
Our GSEA revealed that CRZ2 overexpression turns on and off the
hypoxic and cellular respiration transcriptional signatures, respectively
(Figure 4b). We challenged growth of the CRZ2 overexpression strain
with Antimycin A, as C. albicans strains with reduced respiratory
activity should show reduced sensitivity to this respiratory chain
complex III inhibitor (Desai, van Wijlick, Kurtz, Juchimiuk, & Ernst,
2015; Figure 7a). Strikingly, a PTDH3‐CRZ2 strain overexpressing
CRZ2 under the control of the constitutive PTDH3 promoter
(Table S11) displayed marked resistance to Antimycin A (Figure 7a,
+ Antimycin A panel, compare CIp10 to CIp10‐PTDH3‐CRZ2). This phe-
notype was reproduced with the PTET‐CRZ2 strain following addition
of anhydrotetracycline (aTc) to themedium (Figure 7a, + aTc +Antimycinsceptibility of CRZ2‐deficient (crz2Δ/crz2Δ) and CRZ2‐overexpressing
y on SD plates supplemented with 20 μg ml−1 antimycin A or with
carrying (CIp10 and CIp10‐PTET‐GTW) and CRZ2/CRZ2 strains were
b) Tetrazolium salt‐ (2,3,5‐triphenyltetrazolium chloride) containing
n deficiency (final 0.05% triphenyltetrazolium chloride)
10 of 21 ZNAIDI ET AL.A panel, compare CIp10‐PTET‐GTW to CIp10‐PTET‐CRZ2). In contrast,
loss of CRZ2 resulted in increased sensitivity to Antimycin A (Figure 7
a, compare CRZ2/CRZ2 and crz2Δ/crz2Δ). We further confirmed the
respiration deficiency phenotype of the CRZ2‐overexpressing strains
using the triphenyltetrazolium chloride (TTC) overlay assay (Figure 7
b), whereby reduction of TTC by the electron transport chain leads to
the formation of a red product that accumulates within cells (Rich,
Mischis, Purton, & Wiskich, 2001). As expected, the PTDH3‐CRZ2 strain
lacked the characteristic red/pink colour indicative of efficient respira-
tory activity in both aTc‐free and aTc‐supplemented media (Figure 7b,
compare CIp10 to CIp10‐PTDH3‐CRZ2), whereas the PTET‐CRZ2 strain
displays respiratory deficiency only in the presence of aTc (Figure 7b,
compare CIp10‐PTET‐GTW to CIp10‐PTET‐CRZ2). Thus, CRZ2 expres-
sion appears to control respiratory activity in C. albicans.2.8 | CRZ2 deletion alters the expression of Crz2p
targets in response to hypoxia at 37°C
Based on the altered respiration of the CRZ2 overexpression and
deletion strains and the impact of CRZ2 overexpression on the induc-
tion of the hypoxic program, we hypothesised that CRZ2 could contrib-
ute to regulating adaptation to hypoxia when C. albicans is exposed toFIGURE 8 CRZ2 deletion alters the expression of Crz2p targets in resp
(descending signal intensity, left panel) or downregulated (ascending signa
(Wild‐type) following a shift from normoxia at 30°C to hypoxia at 37°C an
mutant derivative (crz2Δ/crz2Δ) subjected to the same environmental pert
significant differential expression in the wild‐type strain as compared with
Genes are indicated with their corresponding name (or orf19 nomenclatur
promoter was bound by Crz2p in ChIP‐on‐chip assay (Table S9). Heat map
The expression of MNN1, UTR2, PGA6, PHO84, RHD1, and ACT1 (control) d
normoxia at 30°C in the wild‐type strain (Wild‐type, light grey bars) versu
quantitative reverse transcription polymerase chain reaction. Bars represen
and error bars denote standard deviations (n = 3 independently grown str
expression levels as compared with the corresponding ACT1 control using
****P < 0.0001)the GI tract environment.We analysed the transcriptome of a wild‐type
strain relative to that of a crz2Δ/crz2Δ mutant, both grown under
normoxia 30°C or under hypoxia 37°C (Figure 8a, Table S6, see Section
4, 37°C being combined with hypoxia to mimic the GI tract environ-
ment). We found that the expression levels of CRZ2 itself were
~10‐fold induced (Figure 8a, Table S6), correlating with those reached
using PTET‐driven overexpression (approximately eightfold induction,
Figure 4a and Table S6). Importantly, the expression of many Crz2p
bound targets was altered in the crz2Δ/crz2Δmutant as compared with
the wild‐type strain (Figure 8a, asterisks). The crz2Δ/crz2Δ mutant
failed to fully activate or maintain the expression of a subset of PTET‐
CRZ2‐upregulated genes, such as MNN1, RME1, PLB4.5, UTR2, PGA6,
orf19.6350, and orf19.3988 (Figure 8a and Table S6). Similarly, a subset
of the PTET‐CRZ2 downregulated genes displayed altered expression
in the crz2Δ/crz2Δ mutant, including WH11, IFE2, ALD6, GAL10,
PHO84, RHD1, orf19.3721, orf19.2959.1, and orf19.3722 (Figure 8a
and Table S6). We performed a qRT‐PCR assay to confirm our observa-
tions using primers that specifically amplify reverse‐transcribed RNA
from MNN1, UTR2, PGA6 (upregulated in PTET‐CRZ2), PHO84, RHD1
(downregulated in PTET‐CRZ2), and ACT1 (control, Figure 8b). Taken
together, our data indicate that an oxygen‐scarce environment at
37°C induces transcriptional regulation by Crz2p.onse to hypoxia at 37°C. (a) Heat maps of the 30 most upregulated
l intensity, right panel) genes in a CRZ2/CRZ2 wild‐type strain
d their corresponding fold‐change intensities in the CRZ2 homozygous
urbation (normoxia 30°C to hypoxia 37°C). All displayed genes show
the crz2Δ/crz2Δ mutant by analysis of variance analysis (P < 0.05).
e) on the right side of each panel. Asterisks (*) indicate genes whose
s were constructed using Genesis version 1.7.6 (Sturn et al., 2002). (b)
uring growth under hypoxia at 37°C relative to their expression under
s the crz2Δ/crz2Δ mutant (crz2Δ/crz2Δ, black bars) was quantified by
t the average relative change in RNA abundance of the indicated genes,
ains in each condition). Asterisks indicate significantly different gene
a standard Student's t test (*P < 0.05; **P < 0.01; ***P < 0.001;
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37°C alters Candida albicans sensitivity to highly acidic
pH and bile salts
Candida albicans adapts to different niches of the GI tract by
optimising its growth and metabolism according to various parame-
ters, including oxygen availability, pH variation (acidic in upper GI
tract), bile‐salt, and (micro‐) nutrient availability (Noble, 2013; Perez
& Johnson, 2014; Prieto, Correia, Pla, & Roman, 2016). Our observa-
tion that CRZ2 is required for early colonisation of the GI tract could
reflect an adaptive response of C. albicans to the upper section of
the GI tract, including the stomach and proximal intestine, where pH
is highly acidic and bile salts are abundant, respectively (Begley,
Gahan, & Hill, 2005). We tested whether genetic perturbation of
CRZ2 alters C. albicans susceptibility to highly acidic pH (pH 3,
Figure 9). We combined different temperature and oxygen‐availability
parameters to further examine the specificity of the CRZ2 phenotypes
to hypoxia 37°C. As previously observed by Kullas et al. (2007), two
independent crz2Δ/crz2Δ mutants already displayed sensitivity to
acidic pH (Figure 9, upper panel). This phenotype was independent
of growth temperature and oxygen availability (Figure 9, upper panel).
Strikingly, strains overexpressing CRZ2 showed marked resistance to
acidic pH only under hypoxia 37°C (Figure 9, upper right panel,
hypoxia 37°C), reinforcing the notion that CRZ2 exerts its optimal
activity under this condition.
We similarly tested the susceptibility of CRZ2 overexpression and
deletion strains on bile‐salt containing medium (Figure 9, lower panel).
Growth of all tested strains was unaltered under normoxia 30°C,
normoxia 37°C, and hypoxia 30°C (Figure 9, lower left and middle
panels). Importantly, under hypoxia 37°C, the CRZ2 deletion strainsFIGURE 9 CRZ2 is required for adaptation to acidic pH and bile salts un
susceptibility phenotypes of two independent crz2Δ/crz2Δ (#1 and #2) an
analysed together with two independent PTDH3‐driven CRZ2 overexpresse
plates supplemented with 150 mM HEPES at pH 3 and 0.1% bile salts, resp
during hypoxia at 30°C or at 37°C for 2 and 7 days, respectivelydisplayed increased sensitivity to bile salts, whereas the CRZ2 overex-
pression strains were markedly resistant to the same compound
(Figure 9, lower right panel, hypoxia 37°C). Both pH 3 and bile‐salt
phenotypes were unlikely to reflect a more general CRZ2‐dependent
stress sensitivity occurring under hypoxia 37°C, as growth of the
corresponding strains on media containing cadmium (ER stress inducer)
or copper (oxidative stress inducer) was not altered (Figure S5).
Taken together, our results further reinforce the requirement of
hypoxia 37°C for Crz2p to optimally exert its function and suggest
an important role of CRZ2 in C. albicans adaptation to stresses encoun-
tered in the upper sections of the GI tract.2.10 | CRZ2 overexpression confers sensitivity to the
N‐glycosylation inhibitor tunicamycin and alters
phosphomannan abundance
Our finding that Crz2p directly regulates the expression of both
mannosyltransferase‐ and cell wall‐encoding genes led us to
hypothesise that Crz2p could exert its protective role against stresses
encountered in the upper GI tract by interfering with pathways affect-
ing protein glycosylation. We tested the susceptibility of the CRZ2
overexpression strain to the N‐glycosylation inhibitor tunicamycin,
which blocks N‐glycosidic protein‐carbohydrate linkages, using a
microtiter plate assay (Figures 10a, see Section 4). Under normoxia
30°C, two independent PTDH3‐CRZ2 strains were more susceptible to
increasing concentrations of tunicamycin (Figure 10a, upper panel)
than was the control or the crz2Δ/crz2Δmutant strains. As this pheno-
type could also be a consequence of tunicamycin‐induced ER stress
(e.g., unfolded protein response), we also examined the susceptibility
of the PTDH3‐CRZ2 strain to another potent inducer of ER stress,der hypoxia at 37°C. pH 3‐ (upper panels) and bile salt‐ (lower panels)
d the corresponding wild‐type control (CRZ2/CRZ2) strains were
rs and the matched control strain (PTDH3‐GTW) by spot assay on SD
ectively. Plates were incubated under normoxia at 30°C or at 37°C and
FIGURE 10 CRZ2 overexpression interferes with pathways involved
in protein glycosylation. (a and b) Tunicamycin (a) and dithiothreitol (b)
susceptibilities of two independent parental (CRZ2 +/+), CRZ2 deletion
(crz2 −/−), and CRZ2 overexpression (PTDH3‐CRZ2) strains under
normoxia at 30°C and hypoxia at 37°C were determined by microtiter
plate assay. The data are presented as the relative growth of the cells
in tunicamycin‐ or dithiothreitol‐containing medium (drug
concentration range is shown on top of each panel) as compared with
growth of the same strain in drug‐free medium. The growth rate
values (%) are illustrated using heat maps generated with Genesis
version 1.7.6 (Sturn et al., 2002). (c) Alcian Blue binding assay. The
reference strain BWP17 (wild‐type control, CRZ2/CRZ2), two
independent crz2 deletion strains (crz2Δ/crz2Δ #1 and crz2Δ/crz2Δ
#2) together with strains overexpressing CRZ2 from the TDH3
promoter (CIp10‐PTDH3‐CRZ2 #1 and CIp10‐PTDH3‐CRZ2 #2), and the
corresponding parental strain harbouring the empty vector control
(CIp10) were grown under normoxia 30°C (open bars) or under
hypoxia 37°C (filled bars) and then subjected to Alcian Blue dye
binding assay as described in Section 4. Strains are indicated on the x
axis, and the corresponding Alcian Blue binding values (μg/OD600) are
indicated on the y axis. The assay was performed 3 times
independently with averaged values ± standard deviations
12 of 21 ZNAIDI ET AL.dithiothreitol (Zhang, Heitman, & Chen, 2012) and found no difference
in growth rate inhibition (Figure 10b, upper panel). Under hypoxia
37°C, overexpression and deletion of CRZ2 respectively increased
and decreased tunicamycin sensitivity (Figure 10a, lower panel). The
phenotypes were further validated by spot assay on solid medium
containing tunicamycin (Figure S5). No major growth rate difference
was observed when strains were grown under the same conditions
in the presence of increasing concentrations of the ER stress‐inducing
agent dithiothreitol (Figure 10b, lower panel), reinforcing again the
specificity of the CRZ2 phenotype to tunicamycin treatment.
To investigate whether the tunicamycin phenotype correlates
with altered glycosylation, we tested the effect of CRZ2 overexpres-
sion on N‐glycan outer chain elaboration, by quantifying
phosphomannan abundance using cell affinity to Alcian Blue dye
(Hobson et al., 2004). We found that CRZ2 overexpression signifi-
cantly decreased phosphomannan abundance under both normoxia
30°C and hypoxia 37°C (Figure 10c), unlike the CRZ2‐deficient and
wild‐type strains. Taken together, our data indicate that CRZ2 overex-
pression interferes with pathways involved in protein glycosylation.3 | DISCUSSION
Systematic gene overexpression is a powerful approach for linking
genotypes to phenotypes and associating genes to biological path-
ways (Chua et al., 2006; Sopko et al., 2006). Gene overexpression
can particularly stimulate a specific activity and mimic gain‐of‐function
mutations (Prelich, 2012). Our collection includes 572 strains (near
10% genome‐coverage), each overexpressing one single ORF, using
the potent pNIMX tetracycline‐inducible expression system (Chauvel
et al., 2012). Our previous study identified only five genes whose
overexpression altered C. albicans fitness out of 531 competitively
grown signature‐tagged strains, in vitro, using the moderate pNIM1
overexpression system (Cabral et al., 2014). Here, in addition to the
previously identified genes (Cabral et al., 2014), we found 21
overexpressers with altered fitness, indicating that increasing overex-
pression levels correlates with increased sensitivity of our assay.
These data also indicate that at least ~10% of the C. albicans genome
is still relatively robust to genetic perturbation by gene overexpres-
sion, even if we witnessed an increase in the number of hits (5 out
of 531 vs. 25 out of 572; Cabral et al., 2014). Consistent with our pre-
vious findings, we did not detect genes whose overexpression
increased fitness, probably because cells were grown under optimal
in vitro growth conditions (YPD, 30°C, normoxia). Our assay also
revealed that overexpression of a significant number of genes alters
cellular morphology and this appears to translate into a fitness cost
(Figure 2a,c). Many of the genes whose overexpression altered cell
morphology were also found in our previous screen that analysed both
fitness and morphogenesis of individually grown strains, including
RAD53, FKH2, BEM1, and YCK2 (Chauvel et al., 2012). This further
validates our competitive assay and our readout approach.
Although 572 overexpression strains were competitively screened
in vivo for altered GI tract colonisation, only one hit was found to
affect this process: CRZ2. This finding was unexpected, knowing
that our collection includes a subset of some additional regulators
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EFH1 (Table S1). It is possible that the inherent noise generated
through animal experimentation prevented the clear detection of
these genes in our screen. Alternatively, longer colonisation time
(>10 days) might have been required to resolve their overexpression
phenotype, and this was shown in a previous loss‐of‐function screen,
where the identified hits altered GI colonisation at different time
points of stool collection (Perez et al., 2013). For instance, RTG1 dele-
tion phenotype showed up on Day 9 following strain‐pool inoculation,
whereas those of LYS144 and EFH1 required extended time (Day 21
and upwards, Perez et al., 2013). As most of the known regulators of
GI tract colonisation were identified through loss‐of‐function screens,
another explanation is that gene overexpression does not necessarily
lead to inversion of the gene‐deletion phenotype (Hoon et al., 2008).
We could also have selected for strains with disadvantage in colonisa-
tion, including perhaps the fitness defect genes that were already
detected in vitro (Figure 2). We believe that, in vitro, cells are under
optimal growth in rich medium (with preferential carbon source, com-
plete nutrient broth), which allows the detection of subtle phenotypes.
In the gut, however, the different stresses encountered during coloni-
sation and adaptation to those stresses could have masked the effect
of the fitness‐defect genes that were seen in vitro.
CRZ2 encodes a zinc finger TF of the C2H2 family specifically
present among species of the CTG clade that also include commensal
species residing in the gut of insects, such as Pichia stipitis, Candida
tenuis, and Spathaspora passalidarum (Wapinski, Pfeffer, Friedman, &
Regev, 2007). Although Crz2p is homologous to the calcineurin target
Crz1p, it is not involved in calcium signalling (Karababa et al., 2006;
Kullas et al., 2007), and its function has likely diverged from Crz1p
through duplication of a common ancestor (Wapinski et al., 2007).
Here, we propose that Crz2p contributes to C. albicans adaptation
during early days of GI tract colonisation, because the 1:1 competitive
fitness advantage and defect of the CRZ2 overexpression and deletion
strains, respectively, was not maintained during prolonged colonisa-
tion (i.e., >4–10 days, Figures 3c,d and S2B,C). A similar observation
was reported for Wor1p, the regulator of the GUT phenotype (Pande,
Chen, & Noble, 2013), where WOR1 overexpression increased com-
petitive GI colonisation only within 14–21 days post‐inoculation
(Prieto, Roman, Alonso‐Monge, & Pla, 2017). Failure of WOR1
overexpressers to maintain normal levels of GI colonisation during
early days was explained by their increased sensitivity to bile salts
(Prieto et al., 2017), suggesting that they are more fit for lower
sections of the gut rather than upper sections where bile salts are
excreted. Consistent with the hypothesis of preferential colonisation
of the upper digestive tract, we show here that CRZ2 deletion and
overexpression respectively increases and decreases C. albicans sensi-
tivity to bile salts and acidic pH (Figure 9), which probably explains the
early competitive growth advantage and defect of CRZ2 overexpres-
sion and deletion strains, respectively (Figure 3c,d). This reinforces
the notion that different stages of fungal colonisation occur in the
mammalian gut environment, as previously described (Prieto & Pla,
2015; Prieto et al., 2017). The complex network of TFs involved in
GI tract colonisation that currently includes Wor1p, Efg1p, Efh1p,
Cph2p, Lys144p, Tye7p, Rtg1p, Rtg3p, Hms1p, Sfu1p, Zcf8p, Zfu2p,
Try4p (Bohm et al., 2017; Chen, Pande, et al., 2011; Perez et al.,2013; Pierce, Dignard, Whiteway, & Kumamoto, 2013; Rosenbach
et al., 2010; White et al., 2007), and Crz2p suggests that C. albicans
has evolved an extended array of regulators probably acting as relays
needed for efficient and sustained growth during early and later
processes of C. albicans outgrowth in the GI tract.
We show here that CRZ2 is transcriptionally induced by hypoxia
at 37°C (Figure 8a) and that forced overexpression of CRZ2 allows
to confer resistance to the respiratory chain inhibitor Antimycin A
(Figure 7a) in addition to altering reduction of TTC (Figure 7b); rein-
forcing the notion that the optimal activity of Crz2p occurs under con-
ditions where oxygen is limited. Following a shift to hypoxia at 37°C,
the expression of CRZ2 reached levels (~10‐fold, Figure 8a) similar to
those observed upon PTET‐driven overexpression (approximately
eightfold at 4 hr post‐induction, Figure 4a). This indicates that our
overexpression system successfully recapitulated the levels attained
via physiological activation of Crz2p by hypoxia 37°C, reinforcing
the biological relevance of our experimental strategy. How exactly
Crz2p adapts to hypoxic conditions awaits further investigations.
One of the direct Crz2p targets that may contribute to adaptation to
hypoxia and modulation of carbohydrate metabolism is TYE7
(Figure 6), encoding a basic helix–loop–helix TF involved in transcrip-
tional regulation of glycolytic genes (Askew et al., 2009; Bonhomme
et al., 2011). Indeed, Tye7p function was shown to be essential when
the respiratory pathway is disrupted, such as in the presence of respi-
ratory chain inhibitors or during growth in a hypoxic environment
(Askew et al., 2009). Importantly, Tye7p plays a role in adherence to
host cells and favours commensal colonisation (Bohm et al., 2017;
Finkel & Mitchell, 2011; Pierce et al., 2013). It is tempting to
hypothesise that TYE7 could be required, at least in part, for Crz2p‐
mediated GI tract colonisation.
CRZ2 is part of a set of adherence regulators required for adhe-
sion of C. albicans to abiotic substrates, some of them modulating
the expression of CSTAR (cell‐surface targets of adherence regulators)
and HYVIR (hyphal growth or virulence) genes, but CRZ2 could not be
linked to a specific target subgroup (Finkel et al., 2012). One could
speculate that CRZ2 contributes to early gut colonisation by tran-
siently increasing C. albicans adherence to components of the GI envi-
ronment. Many putative mannoprotein‐encoding genes are direct
targets of Crz2p, including PGA6, PGA54, PGA38, IHD1, PHR2, PLB1,
PLB4.5, ECM331, SAP9, UTR2, SUN41, and INT1 (Figure 6) and carry
the N‐glycosylation signature Asn‐X‐Ser/Thr in their predicted protein
sequence (predicted using NetNGlyc version 1.0). Some of them
encode putative adhesins such as PGA6, PGA38, and FGR41 or were
shown to affect C. albicans adhesion to host cells (SAP9, UTR2, and
SUN41; Alberti‐Segui et al., 2004; Albrecht et al., 2006; Hiller, Heine,
Brunner, & Rupp, 2007). INT1 encodes an integrin‐like surface protein
required for efficient caecal colonisation in mice (Bendel et al., 2000;
Kinneberg et al., 1999); however, the pleiotropic phenotypes of INT1
make it an unlikely contributor to CRZ2‐specific function. At least
three Crz2p direct targets (Sun41p, Tos1p, and Scw11p), functioning
as secreted β‐1,3‐glucan‐modifying enzymes, were shown to be highly
abundant in culture supernatants of C. albicans grown under a variety
of growth/stress conditions (Heilmann et al., 2013), suggesting that
they rather participate in more general cell‐wall remodelling processes.
However, Crz2p direct targets Utr2p, Plb4.5p, and Pir1p become
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Brul, 2015). Indeed, we show here that CRZ2 confers survival to highly
acidic and oxygen‐scarce environments (Figure 9) similar to those
encountered in the stomach. Although the mean intestinal pH in
rodents is lower than that in man, the mouse stomach is particularly
highly acidic (pH 3 to 4; McConnell, Basit, & Murdan, 2008). Crz2p
directly controls the expression of PHR2 (Figure 6), encoding a cell‐
wall β‐glycosidase that is expressed at acidic pH (Muhlschlegel &
Fonzi, 1997) and was shown to be required for virulence in a rat model
of vaginal infection (De Bernardis, Muhlschlegel, Cassone, & Fonzi,
1998). Many Crz2p direct targets were also expressed at the
C. albicans cell wall under hypoxia at 37°C in a vagina‐simulative
medium (Sosinska et al., 2008) as well as in an in vitro system that
mimics colonisation of mucosal surfaces at acidic pH, including
PHR2, ECM331, PIR1, UTR2, and TOS1 (Sosinska et al., 2011), further
reinforcing the notion that Crz2p is an important contributor to
C. albicans ability to grow in low‐pH environments.
Candida albicans adaptation to the mammalian gut is tightly
linked to nutritional requirements, such as the need for preventing
iron toxicity (Chen, Blyth, Sorrell, & Slavin, 2011), the use of amino
acids/allantoate and carbohydrates as a source of energy (Perez
et al., 2013), and the catabolism of fatty acids/N‐acetylglucosamine
or phosphate uptake (Pande et al., 2013; Pierce et al., 2013). It is also
linked to the ability of preventing bile‐salt toxicity, particularly in the
upper section of the gut. CRZ2 confers increased resistance to bile
salts (Figure 9), which is considered a major selective pressure
that shapes the structure of the microbial communities residing in
the gut (Ridlon, Harris, Bhowmik, Kang, & Hylemon, 2016). Many
bacterial species that colonise the GI tract play a role in bile salt
metabolism and are able to make bile salts available as substrates
for further modifications by the intestinal microbiota, mainly through
the activity of bile salt hydrolases (Urdaneta & Casadesus, 2017). Our
inspection of the fungal genomes suggests that the genome of only
one Candida species, Candida kefyr, encodes a putative bile salt
hydrolase (GenBank accession # AFC60678.1), whose BLAST analysis
against the C. albicans proteome did not return any significant hit.
Bile‐salt resistance is also conferred by the expression of multidrug
efflux pumps and alteration of membrane lipid/protein composition
(Ridlon et al., 2016). At least 15 Crz2p direct targets encode
membrane transporters (Figure 6), two of which are members of
the major facilitator superfamily: QDR3 and orf19.7554. Qdr3p is
similar to Escherichia coli MdtM, a major facilitator superfamily
drug/H+ antiporter of the DHA1 subfamily that confers bile‐salt resis-
tance through catalysis of electrogenic bile salt/H+ antiport (Paul
et al., 2014). Whether QDR3 confers Crz2p‐mediated resistance to
bile salts awaits further investigation. As CRZ2 genetic perturbation
could affect cell‐wall integrity, one could speculate that it may also
alter the composition of membrane lipids and proteins with the
consequence of decreasing C. albicans susceptibility to bile salts.
We propose that the combined action of the hypoxic environment
within the GI tract and the required adaptation to low pH and bile‐
salt toxicity in the upper digestive tract are crucial for CRZ2's role
in C. albicans ability to thrive within the gut. Our findings and those
already reported by others suggest that C. albicans adaptation to
the gut is a complex process requiring tight and combined controlof sensing abilities, extended morphological and metabolic activities,
and specific adaptive responses.4 | EXPERIMENTAL PROCEDURES
4.1 | Candida albicans strains
The C. albicans signature‐tagged overexpression collection was con-
structed as described previously (Cabral et al., 2014; Chauvel et al.,
2012; see Table S1 for a list of all ORFs included and corresponding
barcode sequences and Table S11 for additional strains used in this
study). Briefly, the respective ORFs were PCR amplified using previ-
ously designed chimeric primers (Cabral et al., 2014) followed by
recombination‐mediated transfer into the Gateway donor vector
pDONR207 (Invitrogen). The set of pDONR207 derivatives was fully
sequenced to ascertain that no unintended mutations were introduced
during PCR amplification. The pDONR207‐ORF plasmids were then
used in a Gateway LR reaction together with barcoded derivatives of
the CIp10‐PTET‐GTW vector (Cabral et al., 2014; Chauvel et al.,
2012). All barcoded overexpression vectors were linearised with StuI
and used to transform strain CEC2908, a derivative of the BWP17AH
strain that carries the pNIMX plasmid (isogenic to CEC2907 described
in Chauvel et al., 2012, Table S1). Transformants were selected and
checked by PCR for correct integration yielding 572 overexpression
strains (Table S1). Seven strains carried altered barcode sequences
and were therefore omitted from the microarray analyses (Table S1,
strains marked in red). The barcoded CIp10‐PTET‐CRZ2 or CIp10‐
PTET‐GTW control plasmids were used to transform strains CEC3783
or CEC3781 (Cabral et al., 2014) carrying the pNIMX plasmid for
doxycycline‐regulated expression from the PTET promoter and either
a PTDH3‐BFP or PTDH3‐GFP gene fusion for constitutive expression of
BFP or GFP, respectively, generating strains CEC4442 or CEC4439,
respectively (Table S11).
The C. albicans crz2Δ/crz2Δ mutants were generated in the
BWP17 (ura3, arg4, and his1 auxotroph) background by successive
replacement of the complete ORF from both alleles using PCR‐
generated disruption cassettes flanked by 100 bp of target homology
region as previously described (Gola, Martin, Walther, Dunkler, &
Wendland, 2003). The disruption cassettes were amplified using oligo-
nucleotides CRZ2_F_KO and CRZ2_R_KO (see Table S12 for primers
used in this study) and ARG4‐ or HIS1‐bearing plasmids. The resulting
transformants were verified by PCR, and two independent clones
were selected for subsequent transformation with plasmid CIp10 or
plasmid CIp10‐PTDH3‐GFP yielding the prototrophic crz2Δ/crz2Δ
mutants C89 and C90 (two independent CIp10 plasmid integrants)
or CEC4263 and CEC4265 (CIp10‐PTDH3‐GFP integrants that
constitutively express GFP), respectively (Table S11). Strain CEC155
(Table S11; Firon et al., 2007) was first transformed with a PCR‐
amplified DNA fragment carrying both PTDH3‐BFP fusion and HIS1
marker such that the whole cassette integrates between the PGA62
and PGA59 loci, as previously described (Cabral et al., 2014). The
resulting strain was transformed with plasmid CIp10 to generate the
prototrophic strain CEC4425 (Table S11) that we used as a BFP‐
labelled control for our 1:1 competitive assays (Figure 3c,d). Strains
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erated by transferring the CRZ2 ORF from the respective pDONR207
derivative to the Gateway‐compatible CIp10‐PTDH3‐GTW plasmid
(Legrand et al. 2018) followed by transformation of strain BWP17AH
(CEC161; Chauvel et al., 2012) to generate three independent PTDH3‐
driven CRZ2‐overexpression clones (C26, C27, and C28; Table S11).
The CEC161 strain was also transformed with CIp10‐PTDH3‐GFP, gen-
erating strain CEC4267 (Table S11), to serve as a control for pheno-
typic assays.
To create a TAP epitope‐tagged version of CRZ2, the CRZ2
ORF was transferred from the corresponding pDONR207 to the
Gateway‐compatible CIp10‐PTET‐TAP‐GTW that allows PTET‐driven
expression of N‐terminally‐tagged ORFs (Legrand et al., 2018, in
press). The ura3 auxotrophic derivative of the crz2Δ/crz2Δ mutants
was first transformed with plasmid pNIMX then with CIp10‐PTET‐
TAP‐CRZ2 or CIp10‐PTET‐CRZ2 (untagged control) to generate
strains C251, C252 (two independent TAP‐tagged clones) and C255,
C257, C258 (three independent untagged control clones), respectively
(Table S11). Expression of the TAP‐Crz2p fusion was confirmed by
Western blotting as described in Znaidi et al. (2013).4.2 | Preparation of strain pools
The 572 signature‐tagged overexpression strains were thawed on
Nunc omnitray plates (Thermo Scientific) containing YPD (1% Yeast
Extract, 2% Bacto‐Peptone, 2% D‐glucose)‐agar supplemented with
50 μg ml−1 gentamycin using a 96 pin replicator and allowed to grow
for 4 days at 30°C. No major colony size alterations were noticed. Five
millilitres of YPD were added to each plate, and colonies were scraped
off using a cell spreader. Strains were pooled in ~100 ml YPD/15%
glycerol at a concentration of ~50 or ~132 OD600 (optical density at
600 nm) units/ml, aliquoted in 1.5‐ml tubes and frozen at −80°C.4.3 | In vitro competitive fitness assay
An aliquot (1.6 μl) from the frozen 50 OD600‐unit strain‐pool was used
to inoculate 2 ml of YPD medium (starting OD600 = 0.0625) and grown
at 30°C with agitation (200 rpm) for 20 generations, in the absence or
presence of 40 μg ml−1 doxycycline. Genomic DNA was extracted
using the MasterPureYeast DNA Purification Kit (Epicentre) and quan-
tified using a NanoVue Plus device (GE Healthcare Life Sciences).
Barcodes were PCR‐amplified using primers CipSAC2‐UP‐2 and
CipSAC2‐DWN‐2 (3 min at 94°C; followed by 35 cycles of 30 s at
94°C, 30 s at 50°C, and 30 s at 72°C; and a final step of 7 min at
72°C; Table S12). The PCR products were then purified and subjected
to indirect differential fluorescent dye labelling (Cy5 for Dox‐treated,
Cy3 for untreated pools). Labelled DNA was resuspended in 50 μl
DigEasy Hyb solution (Roche), incubated at 95°C for 5 min, snap‐
cooled on ice, and directly deposited on a barcode microarray that
we previously described (Agilent Technologies, GEO platform #
GPL17420; Cabral et al., 2014) containing (a) ~12 on‐chip replicates
of both sense and antisense DNA sequences complementary to 657
tags (representing 572 strain tags +78 unused tags) and (b) different
negative control spots (Agilent reference). Hybridization was per-
formed overnight at 25°C, followed by washing and scanning of thearrays using GenePix 4200 AL scanner (Molecular Devices). This
experiment was performed 3 times independently. Microarray data
were analysed using ArrayPipe v2.0 (Hokamp et al., 2004). Z‐score
(i.e., number of standard deviations from the population mean)
calculations were performed using ArrayPipe v2.0, and thresholds for
considering significant deviation from the population were set at abso-
lute Z‐score values ≥2 and P values <0.05. Only strains with tags that
met thresholds for both sense‐ and antisense‐barcode fluorescence
signals were considered as altered in cell fitness. Microarray data have
been deposited at GEO under accession number GSE67215, and
Z‐scores and fold‐change data are available in Table S2.4.4 | Confirmation of the in vitro fitness‐profiling
data by liquid growth assay or microscopic
examination
Strains were individually grown 3 times independently in 96‐well
plates at a starting optical density (OD600) of 0.1 in 100 μl of YPD
supplemented or not with 40 μg ml−1 doxycycline. The OD600 was
measured every 5 min using a TECAN Infinite M200 reader. The
temperature was set at 30°C. TECAN OD600 readings were
converted into “flask OD600” reading using the following formula:
ODFlask = ODTecan × 12.2716 – 1.0543 (Ericson, Hoon, St Onge,
Giaever, & Nislow, 2010), and doubling times were calculated within
the exponential growth interval as previously described (St Onge
et al., 2007). Strains displaying altered morphology or cell–cell
aggregation phenotypes were microscopically examined with a Leica
DM RXA microscope (Leica Microsystems) at a 40× magnification.
Images were captured with a Hamamatsu ORCA II‐ER cooled CCD
camera, using the Openlab software version 3.5.1 (Improvision Inc.).4.5 | In vivo competitive GI tract colonisation screen
All animal experiments adhered to the EU Directive 86/609 on the
approximation of laws, regulations, and administrative provisions of
Member States regarding the protection of animals used for experi-
mental and other scientific purposes and to related national regula-
tions. All experiments were performed according to the guidelines of
the European Convention for the Protection of Vertebrate Animals
used for Experimental and Other Scientific Purposes (ETS # 123).
The protocol was approved by Institut Pasteur Health Center Animal
Care Committee (protocol number 10.455). Nine‐ to 12‐weeks‐old
female BALB/c (Charles River, France) were given drinking water con-
taining 5% sucrose, 0.1 mg ml−1 gentamycin, and 2 mg ml−1 strepto-
mycin and was supplemented or not with 2 mg ml−1 doxycycline,
during the course of the whole experiment (14 days). Mice were
housed by groups of three to five individuals per cage and were
inoculated by gavage with 5 × 107 C. albicans cells (in 200 μl 1X phos-
phate‐buffered saline [PBS] buffer) from 572‐strain pools at Day 4
post‐antibiotic treatment. The remaining inoculum was directly used
for genomic DNA extraction using the MasterPure Yeast DNA Purifi-
cation Kit (Epicentre). Stool samples were collected at Day 10 post‐
gavage, weighed, and either (a) homogenised then serially diluted in
1 ml 1X PBS (2 stool pellets) for CFU counting on YPD plates supple-
mented with 1 g L−1 chloramphenicol and 50 mg L−1 gentamycin
16 of 21 ZNAIDI ET AL.(YPDCG) or (b) directly processed (up to 500 mg of stool pellets)
for genomic DNA extraction using FastDNA SPIN Kit for Faeces
according the manufacturer's instructions (MP Biomedicals, cat. #
6570). Colonisation efficiency was within the range of ~106 to ~108
CFUs per 1 g of stool on Day 10. Barcodes were directly amplified
from dox‐treated (Cy5‐labelled), dox‐untreated (Cy5‐labelled) mouse
stool‐derived, and inoculum‐derived (Cy3‐labelled) genomic DNA
preps using primers CipSAC2‐UP‐2 and CipSAC2‐DWN‐2 and proc-
essed for hybridization to barcode microarrays as described above
(Section 4.3). Data were analysed as described above (Section 4.3).
Microarray data have been deposited at GEO under accession number
GSE67215, and Z‐scores and fold‐change data are available in
Tables S3 and S4. An overview of the design of the competitive fitness
profiling experiment in mice is shown in Figure S1.4.6 | Validation of the GI tract colonisation screen
Q‐PCR assays were performed to quantify the relative abundance of
strains carrying PTET‐CRZ2 (test), PTET‐PGA37, PTET‐orf19.3088, PTET‐
CNB1, and PTET‐IHD1 (controls) using genomic DNA extracted from
pooled stools at Day 10 post‐gavage from two independent dox‐
treated and dox‐untreated cages (each housing three mice) relative
to the inoculum. Forward primers CRZ2‐BC, PGA37s‐BC,
orf19.3088‐BC, CNB1‐BC, and IHD1‐BC (Table S12) complementary
to the 20‐bp barcode sequence of the corresponding strains were used
in combination with the reverse primer CIPSAC2‐DWN3 (Table S12),
which hybridizes 66 bp downstream of each barcode sequence, to
amplify a 106‐bp amplicon in up to 7 independent 20 μl‐Q‐PCR
reactions containing 1 μl genomic DNA (initially, different dilutions
were tested for efficient amplification), 4 μl of primer mix at
10 pmol μl−1 each, 10 μl of 2X Takyon Rox SYBR MasterMix dTTP
Blue (Eurogentec), and 5 μl of H2O. Reactions were processed in a
MicroAmp Optical 96‐Well Reaction Plate (Applied Biosystems) using
an Eppendorf realplex4 Mastercycler real‐time PCR instrument
(Eppendorf) with 1 cycle at 50°C for 2 min, 1 cycle at 95°C for
10 min, and 50 cycles at 95°C for 15 s and 58°C for 1 min, followed
by melting‐curve generation to rule out amplification of unspecific
products. Data were analysed using the realplex software version 2.2
(Eppendorf). For each experiment, threshold cycle (CT) values were
determined using the realplex software. The relative abundance (n‐fold)
of each strain from dox‐supplemented or dox‐free cages as compared
with the inoculum was calculated using the 2−ΔΔCT method, as follows:
ΔCT = CT (selected strain) − CT (TEF3 reference for calibration) in each
condition and ΔΔCT = ΔCT (dox − treated or dox − untreated sam-
ple) − ΔCT (inoculum). The TEF3 gene was used for calibration, and
the ACT1 gene was used as a control for normalisation of C. albicans
DNA abundance (primers TEF3‐F/R and ACT1‐F/R, Table S12). Up to
seven independent qPCR experiments were performed on different
days using two technical replicates each time. A two‐tailed Student's
t test was applied by comparing the relative abundance of each strain
from doxycycline‐treated cages to the untreated controls. Statistical
significance was set at P < 0.05. Data from only one cage are shown in
Figure 3b and are representative of those from the second cage.
To independently validate the CRZ2 overexpression phenotype
and test the effect of CRZ2 deletion on GI colonisation, 5 × 107 cellsfrom a 1:1 mixture of CEC4439 (PTET‐CRZ2, GFP):CEC4442 (PTET‐
empty vector, BFP), CEC4267 (wild‐type, GFP):CEC4425 (wild‐type
control, BFP), CEC4263 (crz2Δ/crz2Δ mutant #1, GFP):CEC4425
(wild‐type control, BFP), or CEC4265 (crz2Δ/crz2Δ mutant #2, GFP):
CEC4425 (wild‐type control, BFP) in 200 μl 1X PBS were used to
inoculate BALB/c or BALB/cByJ mice as described above. The remain-
ing inoculums were analysed by flow cytometry with a MACSQuant
(Miltenyi Biotec) flow cytometer to quantify the relative abundance
of Gfp+ and Bfp+ cells and confirm the near 1:1 distribution of the sig-
nals (see below). For the 1:1 competition using the PTET promoter,
doxycycline at a final concentration of 2 mg ml−1 was added (test) or
not (control) to the drinking water of mice as described above. Stools
were collected at Days 4, 10, and 14 post‐gavage, homogenised and
then serially diluted in 1 ml of 1X PBS (2 stool pellets), and plated
onYPDCG during 2 days at 30°C. Selected dilutions from the resulting
CFUs (typically 400 to 4,000 CFUs) were scraped off using a cell
spreader after addition of 5 ml 1X PBS buffer. The resulting pooled
cells were thoroughly vortexed and diluted 1:1,000 in 1X PBS and
then analysed with the MACSQuant flow cytometer. We used the
405‐ and 488‐nm lasers to excite the BFP and GFP proteins (whose
expression was driven by the TDH3 promoter) and the 425/475 and
500/550 filters to detect the BFP and GFP emission signals. Flow
cytometry outputs were analysed with FlowJo 7.6. Gates that define
the Bfp+ and Gfp+ populations were created with one of the control
samples (dox‐untreated CEC4439:CEC4442 or CEC4267:CEC4425)
and applied to the remaining samples. The percentage values of
Bfp + (%BFP) Gfp + (%GFP) cells were exported to Excel spreadsheets
and further processed. CIs were determined by dividing the ratio of
%GFP (PTET‐CRZ2, wild‐type or crz2Δ/crz2Δ mutants) and %BFP
(PTET‐empty vector, wild‐type control) strains on Days 4, 10, or 14
by the ratio in the inoculum, that is, [(%GFP/ % BFP) at Days 4, 10,
or 14]/[(%GFP/ % BFP) in the inoculum] as previously described
(White et al., 2007). Competitive assays using PTET were performed
up to 4 times independently totalling n = 5 to 12 dox‐untreated mice
and n = 5 to six dox‐treated animals (Figures 3c and S2B, six dox‐
treated mice showed signs of illness and were removed from the
analysis). Two reproducible competition assay experiments were
performed for the crz2Δ/crz2Δ mutants #1 and #2 versus wild‐type
strain (n = 5 mice in each condition, one representative experiment
is shown in Figures 3d and S2C). A two‐tailed non‐parametric
Mann–Whitney test was used for assigning statistical significance
(P < 0.05).4.7 | Whole‐genome transcript profiling experiments
For the PTET‐CRZ2 microarray experiment (Figure 4), total RNA was
extracted from three independently generated crz2Δ/crz2Δ strains
carrying the PTET‐CRZ2 fusion (C255, C257, and C258; Table S11),
pre‐grown overnight in 10 ml YPD at 30°C and then diluted in fresh
YPD medium supplemented or not with 40 μg ml−1 doxycycline to
an OD600 of 0.3 and regrown for 2 and 4 hr. For the normoxia
30°C‐to‐hypoxia 37°C shift microarray experiments (Figure 8), strains
CEC369 (WT) and C90 (crz2Δ/Δ; Table S11) were grown overnight in
10 ml YPD at 30°C and then diluted to an OD600 of 0.16 in 250‐ml
flasks containing 50 ml of YPD medium. The flasks were incubated
ZNAIDI ET AL. 17 of 21in a BBL GasPak anaerobic jar at 37°C for 24 hr without shaking (hyp-
oxia 37°C) or in a 30°C incubator for 24 hr under vigorous shaking
(normoxia 30°C). Total RNA was extracted from 50 OD units using
the hot phenol method as described previously (Znaidi et al., 2013),
followed by first‐strand cDNA synthesis and Cy5 (dox‐treated cDNA
samples for the PTET‐CRZ2 experiment and hypoxia 37°C‐treated
cDNA samples for the normoxia 30°C‐to‐hypoxia 37°C shift experi-
ment)/Cy3 (untreated cDNA samples for the PTET‐CRZ2 experiment
and normoxia 30°C‐treated cDNA samples for the normoxia 30°C‐
to‐hypoxia 37°C shift experiment) labelling from 20 μg total RNA,
using the SuperScript III indirect cDNA labelling system (Invitrogen).
Purified labelled samples were mixed and hybridized to a C. albicans
expression array (Agilent Technologies) designed such that two non-
overlapping probe sets target each of 6,105 C. albicans ORFs from
Assembly 19 for a total of 15,744 probes, thereby allowing two inde-
pendent measurements of the mRNA level for a given gene (Znaidi
et al., 2013). As an additional control experiment, we also compared
the transcriptome of strain C90 (Cy5‐labelled) to that in crz2Δ/Δ
(CEC369, Cy3‐labelled) under normoxia 30°C and under hypoxia
37°C (Table S6). Hybridization was performed as described elsewhere
(Znaidi et al., 2013). Images of the Cy5 and Cy3 fluorescence were
generated by scanning the expression arrays using an Axon Auto-
loader 4200AL scanner (Molecular Devices, Downingtown, PA, USA).
Images were analysed with the GenePix Pro 6.1.0.2 software (Molec-
ular Devices). GenePix Results files were imported into the ArrayPipe
2.0 software for spot filtering, background subtraction (limma
normexp BG correction), and Lowess global normalisation of signal
intensities (Hokamp et al., 2004). Replicate arrays (n = 3) were com-
bined, and fold‐change and P values (standard Student's t test within
group) were calculated. The complete expression profiling datasets
are available in Table S6. Expression microarray data have been
deposited at GEO under accession number GSE67226.4.8 | Chromatin immunoprecipitation and ChIP‐chip
Strains C251, C252 (TAP epitope‐tagged), and C255 and C257
(untagged control; Table S11) were grown overnight in 2 ml YPD at
30°C, diluted to an OD600 of 0.3 in 50 ml YPD medium supplemented
with 40 μg ml−1 doxycycline and grown during 4 hr at 30°C. The
subsequent steps of DNA cross‐linking, DNA shearing, and chromatin
immunoprecipitation (ChIP) were conducted as described in Liu et al.
(2007), with some modifications. Briefly, cultures were treated with
1% formaldehyde (cross‐linking) and snap‐frozen in liquid nitrogen.
Total cell extracts were prepared by bead beating using a FastPrep‐
24 instrument (MP Biomedicals) with 10 runs during 40 s each at
5.5 m s−1 and 1 min on ice in between. Soluble chromatin fragments
were prepared by sonicating the extracts 6 times during 20 s at power
8 (knob position) for an output signal amplitude of 15 (Microns, Peak
to Peak) using a probe sonicator (MSE), yielding a majority of ~200–
500 bp DNA fragments. Immunoprecipitation was conducted over-
night at 4°C with 500 μl of clarified sonicated extracts and 40 μl of
IgG‐coated magnetic beads (Dynabeads Pan mouse IgG, Invitrogen),
previously pre‐hybridized overnight with PBS‐0.1% BSA at 4°C. The
concentration of the purified immunoprecipitated (IP) DNA ranged
between 31 and 147 pg μl−1 in 50 μl TE (10 mM Tris [pH 8.0],1 mM EDTA). DNA was labelled as described by Drouin and Robert
(http://www.ircm.qc.ca/LARECHERCHE/axes/Biologie/Chromatine/
Documents/ProtocoleIRCM_LevureYeast1.pdf). Briefly, the IP DNA
(40 μl out of 50 μl) fragments were blunted withT4 DNA polymerase
and ligated to unidirectional linkers. The DNA was amplified by
ligation‐mediated PCR in the presence of aminoallyl‐modified dUTP.
The labelling was carried out post‐PCR using monoreactive Cy dye
N‐hydroxysuccinimide esters (Cy5/Cy3 monoreactive dye packs;
Amersham Biosciences) that react specifically with the aminoallyl‐
modified dUTP [5‐(3‐aminoallyl)‐2′ deoxyuridine‐5′‐triphosphate;
Sigma‐Aldrich]. Labelled IP DNA from the tagged C251 and C252
strains (Cy5) and the untagged control strains (C255 and C257,
Cy3) were mixed and hybridized to previously described C. albicans
whole‐genome tiled DNA microarrays from Assembly 20 (Tuch,
Galgoczy, Hernday, Li, & Johnson, 2008; GEO platform accession #
GPL13696). Images of Cy5 and Cy3 fluorescence intensities were
generated by scanning arrays using an Axon Autoloader 4200AL
scanner and analysed with the GenePix software version 7.0 (Molec-
ular Devices). Data normalisation (Quantile) and peak finding were
conducted using CisGenome (Ji et al., 2008). The Integrated Geno-
mics Viewer software was used for visualisation of the ChIP‐chip
results (Thorvaldsdottir, Robinson, & Mesirov, 2012; Figure 5a). The
complete Crz2p binding datasets are available in Tables S8–S10.
ChIP‐chip raw data were deposited at GEO under accession number
GSE67233.4.9 | Validation of transcriptomics and ChIP‐chip
experiments
Total RNA from strains C255, C257, and C258 (PTET‐CRZ2 microarray
experiment) or strains CEC369 and C90 (normoxia 30°C‐to‐hypoxia
37°C microarray experiment) was extracted using the hot phenol
method and reverse‐transcribed (5 μg of total RNA) using the Super-
Script III first‐strand synthesis system (Invitrogen, catalogue #
18080‐051) in a total reaction volume of 20 μl. The qPCR reactions
were made of 1 μl from the RT reaction mixture (or diluted RT reac-
tion, when required, to optimise amplification efficiency) combined
with 4 μl of primer mix at 10 pmol μl−1 each (forward and reverse
primers of the selected genes, Table S12), 10 μl of 2X Takyon Rox
SYBR MasterMix dTTP Blue (Eurogentec), and 5 μl of H2O. qPCR
reaction conditions are described above (Section 4.6). For the PTET‐
CRZ2 experiment (at 2 and 4 hr time points), levels of relative gene
expression (n‐fold, for the doxycycline‐treated samples as compared
with the untreated controls) of CRZ2 (primers Crz2_F_qPCR_2 and
Crz2_R_qPCR_2), MNN1 (MNN1‐F/R), PGA6 (PGA6‐F/R), ECM331
(ECM331‐F/R), PLB1 (PLB1‐F/R), RHD3 (RHD3‐F/R), PHO84
(PHO84‐F/R), RHD1 (RHD1‐F/R), and the ACT1 (ACT1‐F/R) negative
control gene (Figure S4) were calculated using the 2−ΔΔCT method, as
follows: ΔCT = CT (selected gene) − CT (TEF3 reference gene),
calculated for both dox‐treated and untreated samples, and
ΔΔCT = ΔCT (doxycycline − treated sample) − ΔCT (untreated sample).
For the normoxia 30°C‐to‐hypoxia 37°C experiment, levels of relative
gene expression (n‐fold, for the hypoxia 37°C samples as compared
with the normoxia 30°C samples in strains CEC369 or C90) of
MNN1 (MNN1‐F/R), UTR2 (Utr2‐RT‐f and Utr2‐RT‐r), PHO84
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control gene (Figure 8b) were calculated using the 2−ΔΔCT method,
as follows: ΔCT = CT (selected gene) − CT (TEF3 reference gene),
calculated for both hypoxia 37°C and normoxia 30°C samples, and
ΔΔCT = ΔCT (hypoxia 37
°C sample) − ΔCT (normoxia 30
°C sample).
For the ChIP‐qPCR experiment, the levels of target‐DNA enrichment
(n‐fold, Table S12 lists primer sequences) for CRZ2 (primers
CRZ2prom‐F/R), MNN1 (MNN1prom‐F/R), ECM331 (ECM331prom‐
F/R), MNN22 (MNN22prom‐F/R), RHD1 (RHD1prom‐F/R), RHD3
(RHD3prom‐F/R), and ACT1 (ACT1‐F/R, used as a negative control)
were calculated using relative quantification according to the 2−ΔΔCT
method, as follows: ΔCT = CT (target) − CT (TEF3 reference),
calculated in both tagged (TAP‐Crz2p, strains C251 and C252) and
untagged (untagged Crz2p, strains C255 and C257) samples, and
ΔΔCT = ΔCT (tagged) − ΔCT (untagged), where CT (TEF3 reference) is
the CT for the TEF3 amplicon (primers TEF3‐F/R, Table S12).
Assays were performed (a) at least 2 times using three biological
replicates for the qRT‐PCR experiments or (b) 3 times independently
with two biological replicates each time. A two‐tailed Student's t test
was applied by comparing, for a given gene/ChIP target, the n‐fold
relative gene‐expression values to the corresponding n‐fold values of
the ACT1 control (Figures S4 and 8b) or, for ChIP‐qPCR, the n‐fold
enrichment values of the selected target gene (CRZ2, MNN1,
ECM331, MNN22, RHD1, or RHD3) to those of the corresponding
ACT1 control (Figure 5b). Statistical significance threshold was
P < 0.05.4.10 | Alcian Blue binding of cell wall mannans
Alcian Blue binding assay was performed as described in Odani,
Shimma, Tanaka, and Jigami (1996). Briefly, cells were grown in YPD
medium at 30°C for 48 hr or at 37°C for 48 hr under hypoxic condi-
tions and then harvested by centrifugation, washed with 0.02 M
HCl, and resuspended in 1 ml of 100 μg ml−1 Alcian Blue HCl solution
(Merck Millipore, Germany). After incubation at room temperature for
10 min, cells were pelleted, and absorbance (OD600) of the superna-
tant was determined in a microplate reader. Alcian Blue binding was
calculated following the formula: (μg/OD600) = 61.3 × (OD600 original
solution − OD600 supernatant)/OD600 cell density.4.11 | Spot and microtiter plate assays
For spot assays, cell patches from strains CEC369 (CRZ2/CRZ2,
control), C89‐C90 (crz2Δ/crz2Δ), C74 (CIp10, control), C26‐C27
(two independently generated CIp10‐PTDH3‐CRZ2 strains), CEC4442
(CIp10‐PTET‐GTW, control), and CEC4439 (CIp10‐PTET‐CRZ2; Table
S11) were grown overnight in YPD medium and resuspended in
water to an optical density at 600 nm of 0.1. Tenfold serial dilutions
of each strain were spotted onto (a) SD or YPD plates supplemented
with 20 μg ml−1 Antimycin A (from Streptomyces sp., A8674‐50MG,
Sigma Aldrich, +/− 3 μg ml−1 aTc) or 2 μg ml−1 of tunicamycin (from
Streptomyces sp., T7765‐5MG, Sigma Aldrich) or (b) SD plates supple-
mented with 150 mM HEPES (Gibco, Invitrogen) buffered at pH 3 or
supplemented with 0.1% bile salts (48305‐50G‐F, Sigma Aldrich). The
plates were incubated for 1–3 days at 30°C or 37°C under normoxicconditions or for 3–7 days at 30°C or 37°C in a BBL GasPak
anaerobic jar. For the microtiter plate assays, cells were grown
overnight in YPD medium and then diluted in YPD to an OD600 of
0.1, followed by a second 1:100 dilution in the same medium. Fifty
microlitres of this dilution was added to 50 μl of a tunicamycin or
dithiothreitol solution (in YPD) concentrated 2 times or drug‐free
medium in 96‐well microtiter plates. The range of drug concentra-
tions tested was 0.15, 0.25, 0.31, 0.50, 0.62, 1.00, 1.25, 2.00, 2.50,
4.00, and 5.00 μg ml−1 of tunicamycin and 0.62, 1.09, 1.25, 2.19,
2.50, 4.37, 5.00, 8.75, 10.00, 17.50, and 20.00 mM of dithiothreitol.
Growth was measured spectrophotometrically at OD600 after 24 hr
of incubation at 30°C in a humid chamber or after 4 days under
hypoxia at 37°C.4.12 | Bioinformatic analyses
GSEA were performed as described previously (Sellam et al., 2014).
Briefly, the GSEA PreRanked tool (http://www.broadinstitute.org/
gsea/) was used (default parameters) to determine if our lists of ranked
genes (PTET‐CRZ2 data at 2 and 4 hr sorted from the highest upregu-
lated genes to the highest downregulated ones) display a significant
bias with any gene sets from a compendium of published microarray
data, GO term categories/pathways, and data derived from S. cerevisiae
resources (Sellam et al., 2014). The Cytoscape EnrichmentMap plugin
was used to further visualise the GSEA network using the default
parameters (Figure 4b,c). For motif discovery analyses, peak summit
location files generated by CisGenome (Tables S8 and S9; Ji et al.,
2008) were imported into the Galaxy NGS analysis pipeline (https://
main.g2.bx.psu.edu/), and DNA sequences encompassing ±250 bp
around peak summits in Crz2p datasets were extracted using the
Extract Genomic DNA tool version 2.2.2. The resulting sequences
together with an equivalent set of randomly chosen sequences from
the C. albicans genome (used as a negative control) were used as input
for motif discovery with the Regulatory Sequence Analysis Tools
(http://rsat.ulb.ac.be/rsat/) peak‐motifs algorithm (Thomas‐Chollier
et al., 2012). Significance coefficients of overrepresented motifs
(sig scores = − log10 [E − value]) are calculated using a binomial test.
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